Patents by Inventor Stephen S. Whitehead

Stephen S. Whitehead has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CONSTRUCTION OF WEST NILE VIRUS AND DENGUE VIRUS CHIMERAS FOR USE IN A LIVE VIRUS VACCINE TO PREVENT DISEASE CAUSED BY WEST NILE VIRUS
    Publication number: 20140294892
    Abstract: The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines.
    Type: Application
    Filed: June 16, 2014
    Publication date: October 2, 2014
    Inventors: Alexander G. Pletnev, Joseph R. Putnak, Robert M. Chanock, Brian R. Murphy, Stephen S. Whitehead, Joseph E. Blaney
  • Construction of West Nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by West Nile virus
    Patent number: 8778671
    Abstract: The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines.
    Type: Grant
    Filed: June 18, 2004
    Date of Patent: July 15, 2014
    Assignees: The United States of America, as represented by the Secretary of the Department of Health & Human Services, The Walter Reed Army Institute of Research
    Inventors: Alexander G. Pletnev, Joseph R. Putnak, Robert M. Chanock, Brian R. Murphy, Stephen S. Whitehead, Joseph E. Blaney, Jr.
  • LIVE ATTENUATED VIRUS VACCINES FOR LA CROSSE VIRUS AND OTHER BUNYAVIRIDAE
    Publication number: 20140023679
    Abstract: The invention relates to vaccine compositions including CEV serogroup immunogens, attenuated and inactivated viruses of the CEV serogroup and chimeric Bunyaviridae. Also disclosed are methods of treating or preventing CEV serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a CEV serogroup immunogen, methods for detecting La Crosse virus (LACV) infection in a biological sample and infectious chimeric Bunyaviridae.
    Type: Application
    Filed: October 2, 2012
    Publication date: January 23, 2014
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Stephen S. Whitehead, Richard S. Bennett, Brian R. Murphy
  • Recombinant attenuated dengue viruses comprising mutations in NS5 and the 3? untranslated region
    Patent number: 8632782
    Abstract: The invention features novel attenuated dengue virus mutants and compositions thereof.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: January 21, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai
  • DENGUE TETRAVALENT VACCINE CONTAINING A COMMON 30 NUCLEOTIDE DELETION IN THE 3'-UTR OF DENGUE TYPES 1, 2, 3, AND 4, OR ANTIGENIC CHIMERIC DENGUE VIRUSES 1, 2, 3, AND 4
    Publication number: 20130011433
    Abstract: The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (?30) in the 3?-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.
    Type: Application
    Filed: November 28, 2011
    Publication date: January 10, 2013
    Applicant: The Government of the USA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Lewis Markoff, Barry Falgout, Joseph Blaney, Kathryn Hanley
  • Development of dengue virus vaccine components
    Patent number: 8337860
    Abstract: The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3? untranslated region (3?-UTR) comprising a ?30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the ?30 mutation deleted from the 3?-UTR that removes sequence in the 5? direction as far as the 5? boundary of the TL-3 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, or a replacement of the 3?-UTR of a dengue virus of a first serotype with the 3?-UTR of a dengue virus of a second serotype, optionally containing the ?30 mutation and nucleotides additional to the ?30 mutation deleted from the 3?-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.
    Type: Grant
    Filed: August 15, 2007
    Date of Patent: December 25, 2012
    Assignee: The United States of America, as represented by the Secretary of the Department of Health & Human Services
    Inventors: Stephen S. Whitehead, Joseph E. Blaney, Brian R. Murphy
  • Live attenuated virus vaccines for La Crosse virus and other Bunyaviridae
    Patent number: 8298541
    Abstract: The invention relates to vaccine compositions including CEV serogroup immunogens, attenuated and inactivated viruses of the CEV serogroup and chimeric Bunyaviridae. Also disclosed are methods of treating or preventing CEV serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a CEV serogroup immunogen, methods for detecting La Crosse virus (LACV) infection in a biological sample and infectious chimeric Bunyaviridae.
    Type: Grant
    Filed: March 6, 2008
    Date of Patent: October 30, 2012
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Stephen S. Whitehead, Richard S. Bennett, Brian R. Murphy
  • DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING DENGUE VIRUSES AND CHIMERIC DENGUE VIRUSES
    Publication number: 20120114694
    Abstract: A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.
    Type: Application
    Filed: September 22, 2011
    Publication date: May 10, 2012
    Applicant: The Government of the USA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney
  • Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3?-UTR of dengue types 1, 2, 3, and 4 or antigenic chimeric dengue viruses 1, 2, 3, and 4
    Patent number: 8075903
    Abstract: The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (?30) in the 3?-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.
    Type: Grant
    Filed: March 4, 2009
    Date of Patent: December 13, 2011
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Lewis Markoff, Barry Falgout, Joseph Blaney, Kathryn Hanley
  • Recombinant attenuated dengue viruses comprising a deletion in the 3? untranslated region and additional attenuating mutations induced by chemical mutagenesis
    Patent number: 8039003
    Abstract: The invention provides compositions featuring an attenuated dengue virus mutant or an attenuated chimeric dengue virus mutant.
    Type: Grant
    Filed: March 2, 2009
    Date of Patent: October 18, 2011
    Assignee: The United States of America as represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney
  • LIVE ATTENUATED VIRUS VACCINES FOR LA CROSSE VIRUS AND OTHER BUNYAVIRIDAE
    Publication number: 20110200630
    Abstract: The invention relates to vaccine compositions including CEV serogroup immunogens, attenuated and inactivated viruses of the CEV serogroup and chimeric Bunyaviridae. Also disclosed are methods of treating or preventing CEV serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a CEV serogroup immunogen, methods for detecting La Crosse virus (LACV) infection in a biological sample and infectious chimeric Bunyaviridae.
    Type: Application
    Filed: March 6, 2008
    Publication date: August 18, 2011
    Applicant: The Government of the United States of America, as Represented by the Secretary Department of Health
    Inventors: Stephen S. Whitehead, Richard S. Bennett, Brian R. Murphy
  • CHIMERIC SLE/DENGUE TYPE 4 ANTIGENIC VIRUSES
    Publication number: 20100316670
    Abstract: Embodiments described herein concern attenuated, St. Louis Encephalitis Virus/dengue virus type 4 antigenic chimeric viruses, which can be used to prepare immunogenic compositions, vaccines, and diagnostic reagents. Methods of making and using the foregoing are provided.
    Type: Application
    Filed: June 10, 2008
    Publication date: December 16, 2010
    Inventors: Joseph E. Blaney, Brian R. Murphy, Alexander G. Pletnev, Stephen S. Whitehead
  • Attenuated chimeric respiratory syncytial virus
    Patent number: 7846455
    Abstract: Chimeric respiratory syncytial virus (RSV) and vaccine compositions thereof are produced by introducing one or more heterologous gene(s) or gene segment(s) from one RSV subgroup or strain into a recipient RSV backround of a different subgroup or strain. The resulting chimeric RSV virus or subviral particle is infectious and attenuated, preferably by introduction of selected mutations specifying attenuated phenotypes into a chimeric genome or antigenome to yield, for example, temperature sensitive (ts) and/or cold adapted (ca) vaccine strains. Alternatively, chimeric RSV and vaccine compositions thereof incorporate other mutations specifying desired structural and/or phenotypic characteristics in an infectious chimeric RSV. Such chimeric RSV incorporate desired mutations specified by insertion, deletion, substitution or rearrangement of one or more selected nucleotide sequence(s), gene(s), or gene segment(s) in a chimeric RSV clone.
    Type: Grant
    Filed: November 25, 2003
    Date of Patent: December 7, 2010
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Peter L. Collins, Brian R. Murphy, Stephen S. Whitehead
  • Production of attenuated, human-bovine chimeric respiratory syncytial virus vaccines
    Patent number: 7842798
    Abstract: Chimeric human-bovine respiratory syncytial virus (RSV) are infectious and attenuated in humans and other mammals and useful in vaccine formulations for eliciting an anti-RSV immune response. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric RSV genome or antigenome which includes a partial or complete human or bovine RSV “background” genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) of a different RSV strain. In preferred aspects of the invention, chimeric RSV incorporate a partial or complete bovine RSV background genome or antigenome combined with one or more heterologous gene(s) or genome segment(s) from a human RSV. A variety of additional mutations and nucleotide modifications are provided within the human-bovine chimeric RSV of the invention to yield desired phenotypic and structural effects.
    Type: Grant
    Filed: August 11, 2005
    Date of Patent: November 30, 2010
    Assignee: The United States of America as represented by the Secretary, Department of Health and Human Services
    Inventors: Ursula Buchholz, Peter L. Collins, Brian R. Murphy, Stephen S. Whitehead, Christine D. Krempl
  • Production of attenuated, human-bovine chimeric respiratory syncytial virus vaccines
    Patent number: 7829102
    Abstract: Chimeric human-bovine respiratory syncytial virus (RSV) are infectious and attenuated in humans and other mammals and useful in vaccine formulations for eliciting an anti-RSV immune response. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric RSV genome or antigenome which includes a partial or complete human or bovine RSV “background” genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) of a different RSV strain. Chimeric human-bovine RSV of the invention include a partial or complete “background” RSV genome or antigenome derived from or patterned after a human or bovine RSV strain or subgroup virus combined with one or more heterologous gene(s) or genome segment(s) of a different RSV strain or subgroup virus to form the human-bovine chimeric RSV genome or antigenome.
    Type: Grant
    Filed: March 31, 2005
    Date of Patent: November 9, 2010
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Ursula Buchholz, Peter L. Collins, Brian R. Murphy, Stephen S. Whitehead, Christine D. Krempl
  • Production of attenuated, human-bovine chimeric respiratory syncytial viruses for use in immunogenic compositions
    Patent number: 7820182
    Abstract: Chimeric human-bovine respiratory syncytial virus (RSV) are infectious and attenuated in humans and other mammals and useful in immunogenic compositions for eliciting an anti-RSV immune response. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric RSV genome or antigenome which includes a partial or complete human or bovine RSV “background” genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) of a different RSV strain. Chimeric human-bovine RSV of the invention include a partial or complete “background” RSV genome or antigenome derived from or patterned after a human or bovine RSV strain or subgroup virus combined with one or more heterologous gene(s) or genome segment(s) of a different RSV strain or subgroup virus to form the human-bovine chimeric RSV genome or antigenome.
    Type: Grant
    Filed: November 7, 2003
    Date of Patent: October 26, 2010
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Ursula Buchholz, Peter L. Collins, Brian R. Murphy, Stephen S. Whitehead, Christine D. Krempl
  • Respiratory syncytial virus vaccines expressing protective antigens from promotor-proximal genes
    Patent number: 7744902
    Abstract: Recombinant respiratory syncytial virus (RSV) having the position of genes shifted within the genome or antigenome of the recombinant virus are infectious and attenuated in humans and other mammals. Gene shifted RSV are constructed by insertion, deletion or rearrangement of genes or genome segments within the recombinant genome or antigenome and are useful in vaccine formulations for eliciting an anti-RSV immune response. Also provided are isolated polynucleotide molecules and vectors incorporating a recombinant RSV genome or antigenome wherein a gene or gene segment is shifted to a more promoter-proximal or promoter-distal position within the genome or antigenome compared to a wild type position of the gene in the RSV gene map. Shifting the position of genes in this manner provides for a selected increase or decrease in expression of the gene, depending on the nature and degree of the positional shift.
    Type: Grant
    Filed: January 10, 2005
    Date of Patent: June 29, 2010
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Christine D. Krempl, Peter L. Collins, Brian R. Murphy, Ursula Buchholz, Stephen S. Whitehead
  • Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
    Patent number: RE45016
    Abstract: A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: July 15, 2014
    Assignee: The United States of America, as represented by the Secretary of the Department of Health & Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai
  • Attenuated dengue virus comprising mutations in the NS3 gene
    Patent number: RE45053
    Abstract: A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: July 29, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai
  • Recombinant attenuated dengue viruses comprising a deletion in the 3? untranslated region and additional attenuating mutations induced by chemical mutagenesis
    Patent number: RE45123
    Abstract: The invention provides compositions featuring an attenuated dengue virus mutant or an attenuated chimeric dengue virus mutant.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: September 9, 2014
    Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai